Compass TherapeuticsCMPX +0.86%23 Debt-to-Equity is 0.05 as of Mar. 2026, which is 25% above its 10-year median of 0.04. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 963 Biotechnology companies, Compass Therapeutics ranks better than 71.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Compass Therapeutics's Debt-to-Equity or its related term are showing as below:
CMPX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.17 Med: 0.04 Max: 0.37
Current: 0.05
During the past 8 years, the highest Debt-to-Equity Ratio of Compass Therapeutics was 0.37. The lowest was -0.17. And the median was 0.04.
CMPX's Debt-to-Equity is ranked better than 71.96% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs CMPX: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Compass Therapeutics Debt-to-Equity Related Terms
Compass Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Compass Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMPX vs XFOR, LRMR, PROK: Debt-to-Equity Comparison
For the Biotechnology subindustry, Compass Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (CMPX) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Compass Therapeutics and its competitors. This is 25% above median its historical median of 0.04. According to the industry distribution chart, Compass Therapeutics ranks #270 out of 963 companies in the Biotechnology industry, placing it in the top 28%.
Is Compass Therapeutics' Debt-to-Equity too high?
Compass Therapeutics' current Debt-to-Equity of 0.05 is 25% above median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. Compass Therapeutics' value of 0.05 is 68.8% below this industry median. Based on the distribution chart, Compass Therapeutics ranks #270 out of 963 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Debt-to-Equity compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #270 out of 963 companies for Debt-to-Equity. This puts Compass Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Compass Therapeutics' value of 0.05 is 68.8% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.16, Compass Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Therapeutics's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Compass Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Therapeutics's current Debt-to-Equity is 0.05, which is 25% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Debt-to-Equity of 0.05. The current Debt-to-Equity is 0.05, which is 25% above median its 10-year median of 0.04 and 68.8% below the Biotechnology industry median of 0.16. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score
Get the complete analysis for CMPX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
